Clinical trials: Advanced Malignant Solid Tumors, active
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Solid Tumor
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors
- Conditions
- Advanced Solid Tumors, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult
- Trial name
- NCT02974738
- Testing
- Belzutifan
- Volunteers
- 120 people
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing.
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT05564377
- Testing
- Alpelisib, Binimetinib, Biopsy Procedure
- Where
- 484 sites in United States, Puerto Rico
- Volunteers
- 2,900 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.
- Trial name
- NCT05765851
- Testing
- DS-1103a, T-DXd
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 128 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumors
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) is a cancer-testis antigen (CTA) which is expressed in various tumors. In TCR-T therapy, researchers take the blood of a certain patient, select T cells and insert genes…
- Trial name
- NCT05881525
- Testing
- TC-N201 cells, IL-2, Fludarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- TCRCure Biopharma Ltd.
Advanced Solid Tumor, Melanoma
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
- Trial name
- NCT06172478
- Testing
- HER3-DXd
- Where
- 96 sites in United States, Australia and 14 more
- Volunteers
- 740 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of KK2269 in Adult Participants With Solid Tumors
This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06266299
- Testing
- KK2269, Docetaxel
- Where
- 32 sites in United States, Japan
- Volunteers
- 83 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
- Conditions
- Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
- Trial name
- NCT06835569
- Testing
- ALTA3263, cetuximab, mFOLFOX6
- Where
- 14 sites in United States
- Volunteers
- 448 people
- Sponsor
- Alterome Therapeutics, Inc.
Advanced Solid Tumors
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 Monotherapy and in Combination with Other Agents in adult participants with advanced solid tumors
- Trial name
- NCT06973564
- Testing
- JAB-23E73, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 344 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Advanced Solid Cancer
Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.
- Trial name
- NCT07196579
- Testing
- KXV01 TCR Lentinvivo Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- TCRx Therapeutics Co.Ltd
Advanced Solid Tumors
Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.
- Trial name
- NCT07275853
- Testing
- KXV01 TCR Lentinvivo Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- TCRx Therapeutics Co.Ltd
Locally Advanced or Metastatic Solid Tumors
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies.
- Trial name
- NCT07730021
- Testing
- ASP388B, Pembrolizumab, Carboplatin
- Where
- 4 sites in United States, Japan
- Volunteers
- 392 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Solid Tumor, Advanced Solid Tumor
An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BON-106 in adults with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT07893535
- Testing
- BON-106
- Volunteers
- 96 people
- Sponsor
- BeOne Medicines
Solid Tumor (Phase I), Ovarian Cancer
A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors.
This study is a open-label, multicenter clinical trials. The target population is participants with locally advanced or metastatic solid tumors. A total of 204 participants are planned to be included.
- Conditions
- Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT07894874
- Testing
- YF550
- Volunteers
- 204 people
- Sponsor
- InventisBio Yiqi Beijing Limited
Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
This phase I/II trial studies the side effects of avelumab when given in different combinations with utomilumab, anti-OX40 antibody PF-04518600, and radiation therapy in treating patients with malignancies that have spread to…
- Conditions
- Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03217747
- Testing
- Avelumab, Ivuxolimab, Radiation Therapy
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- M.D. Anderson Cancer Center
Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
This phase II trial studies how well adavosertib works in treating patients with SETD2-deficient solid tumors that have spread to other places in the body (advanced/metastatic).
- Conditions
- Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03284385
- Testing
- Adavosertib
- Where
- 29 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors
The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability when given as a single medication and as a combined medication in adults with solid tumors, where the…
- Trial name
- NCT07128303
- Testing
- GS-5319, Carboplatin, Pemetrexed
- Where
- 12 sites in United States, South Korea and 1 more
- Volunteers
- 476 people
- Sponsor
- Gilead Sciences
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined…
- Trial name
- KontRASt-R (NCT07468071)
- Testing
- Opnurasib, TNO155, trametinib
- Where
- 21 sites in Belgium, Canada and 8 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor, Metastatic Solid Tumor
First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors
This clinical trial is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy signals of DS1025a, given as a single agent to participants with advanced, metastatic, or…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Unresectable Solid Tumor
- Trial name
- NCT07681882
- Testing
- DS1025a
- Where
- 3 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Daiichi Sankyo
RAS Mutation, Advanced Solid Tumor
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
The purpose of this study is to test if the BG-85738 is safe and if it works in patients with advanced solid tumors with RAS mutations when it is given on its own and in combination.
- Conditions
- RAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT07746141
- Testing
- BG-85738, Tislelizumab, Cetuximab
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 100 people
- Sponsor
- BeOne Medicines